Oncology

October 19, 2022

KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo

20th Annual Discovery on Target Conference

August 24, 2022

Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications

ACS Fall 2022

June 26, 2022

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology

37th ACS National Medicinal Chemistry Symposium

June 7, 2022

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Targeting protein degradation 3 – from discovery to the clinic (TPD3)

June 1, 2022

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

June 1, 2022

Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

April 7, 2022

KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)

American Association for Cancer Research Annual Meeting

December 13, 2021

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

The 63rd Annual ASH Meeting and Exposition

December 13, 2021

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

The 63rd Annual ASH Meeting and Exposition

November 12, 2021

Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition

SITC 2021

Programs & Targets

Indications

Year

Resource Type/Format

Development Stage

KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo

Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition